These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 26853322

  • 1. Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.
    Gragnani L, Piluso A, Urraro T, Fabbrizzi A, Fognani E, Petraccia L, Genovesi A, Giubilei L, Ranieri J, Stasi C, Monti M, Zignego AL.
    Curr Drug Targets; 2017; 18(7):772-785. PubMed ID: 26853322
    [Abstract] [Full Text] [Related]

  • 2. Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
    Boglione L, Cusato J, Pinna SM, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
    Arch Virol; 2018 Apr; 163(4):961-967. PubMed ID: 29318374
    [Abstract] [Full Text] [Related]

  • 3. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
    Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, Perez M, Ceccotti G, Colantuono S, Mitrevski M, Stasi C, Del Padre M, Monti M, Gianni E, Pulsoni A, Fiorilli M, Casato M, Zignego AL.
    Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
    [Abstract] [Full Text] [Related]

  • 4. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
    Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT.
    Hepatology; 2016 Feb; 63(2):408-17. PubMed ID: 26474537
    [Abstract] [Full Text] [Related]

  • 5. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
    Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P.
    Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D.
    Blood; 2010 Jul 22; 116(3):343-53. PubMed ID: 20308602
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
    Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, Stasi C, Ranieri J, Monti M, Arena U, Iannacone C, Laffi G, Zignego AL, MaSVE Study Group.
    Hepatology; 2015 Apr 22; 61(4):1145-53. PubMed ID: 25431357
    [Abstract] [Full Text] [Related]

  • 9. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G.
    J Hepatol; 2005 May 22; 42(5):632-8. PubMed ID: 15826710
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, Wong D, Janssen HLA, Feld JJ.
    Am J Gastroenterol; 2017 Aug 22; 112(8):1298-1308. PubMed ID: 28291241
    [Abstract] [Full Text] [Related]

  • 11. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P.
    Blood; 2010 Jul 22; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [Abstract] [Full Text] [Related]

  • 12. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S.
    Lancet; 2015 Jun 20; 385(9986):2502-9. PubMed ID: 25837829
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.
    J Hepatol; 2017 Jun 20; 66(6):1138-1148. PubMed ID: 28189751
    [Abstract] [Full Text] [Related]

  • 14. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.
    Gragnani L, Cerretelli G, Lorini S, Steidl C, Giovannelli A, Monti M, Petraccia L, Sadalla S, Urraro T, Caini P, Xheka A, Simone A, Arena U, Matucci-Cerinic M, Vergani D, Laffi G, Zignego AL.
    Aliment Pharmacol Ther; 2018 Aug 20; 48(4):440-450. PubMed ID: 29952013
    [Abstract] [Full Text] [Related]

  • 15. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV.
    J Viral Hepat; 2018 Oct 20; 25(10):1180-1188. PubMed ID: 29660224
    [Abstract] [Full Text] [Related]

  • 16. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.
    Rutledge SM, Chung RT, Sise ME.
    Hemodial Int; 2018 Apr 20; 22 Suppl 1():S81-S96. PubMed ID: 29694729
    [Abstract] [Full Text] [Related]

  • 17. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.
    Arch Virol; 2015 Aug 20; 160(8):2009-17. PubMed ID: 26060059
    [Abstract] [Full Text] [Related]

  • 18. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA, Rosenzwajg M, Saadoun D, Trébeden-Negre H, Klatzmann D, Cacoub P.
    Arthritis Rheum; 2008 Sep 20; 58(9):2897-907. PubMed ID: 18759287
    [Abstract] [Full Text] [Related]

  • 19. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
    Calleja JL, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, Yebra M, Escartín P.
    Aliment Pharmacol Ther; 1999 Sep 20; 13(9):1179-86. PubMed ID: 10468699
    [Abstract] [Full Text] [Related]

  • 20. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F, Pradat P, Virlogeux V, Zoulim F.
    Dig Dis; 2015 Sep 20; 33(4):613-23. PubMed ID: 26159282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.